Disease Detail

ID DOID:9261
Name nasopharynx carcinoma
Definition A pharynx cancer that is located in the nasopharynx, the uppermost region of the pharynx or \throat\, where the nasal passages and auditory tubes join the remainder of the upper respiratory tract.
Source DiseaseOntology.org
Alt Ids DOID:9229 DOID:9144 DOID:8813 DOID:8814 DOID:9057 DOID:9197
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer pharynx cancer nasopharynx carcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA amp MK2206 nasopharynx carcinoma sensitive detail...
Unknown unknown WNT-C59 nasopharynx carcinoma not applicable detail...
Unknown unknown Axitinib nasopharynx carcinoma not applicable detail...
Unknown unknown Camrelizumab nasopharynx carcinoma not applicable detail...
Unknown unknown Camrelizumab + Cisplatin + Gemcitabine nasopharynx carcinoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01498484 Phase II EB-VST cells Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies Active, not recruiting
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed
NCT02113878 Phase I Buparlisib + Cisplatin Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck Active, not recruiting
NCT02269943 Phase II Azacitidine Safety and Efficacy of Oral Azacitidine in Previously Treated Subjects With Locally Advanced or Metastatic Nasopharyngeal Carcinoma Completed
NCT02339558 Phase II Nivolumab Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer Active, not recruiting
NCT02358031 Phase III Cetuximab Pembrolizumab Fluorouracil Carboplatin Cisplatin A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) Active, not recruiting
NCT02460224 Phase Ib/II LAG525 Spartalizumab Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Active, not recruiting
NCT02488759 Phase Ib/II Nivolumab A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358) Recruiting
NCT02538510 Phase Ib/II Pembrolizumab + Vorinostat Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer and Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery Active, not recruiting
NCT02605967 Phase II Spartalizumab Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Active, not recruiting
NCT02611960 Phase II Pembrolizumab Capecitabine + Docetaxel + Gemcitabine Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122, KEYNOTE-122) Active, not recruiting
NCT02643550 Phase Ib/II Cetuximab + IPH2201 Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Recruiting
NCT02706691 Phase II BGJ398 Pan FGFR Kinase Inhibitor BGJ398 in Treating Patients With FGFR1-3 Translocated, Mutated, or Amplified Recurrent Head and Neck Cancer Terminated
NCT02780011 Phase I Alisertib + Brentuximab vedotin Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies Withdrawn
NCT02795156 Phase II Cabozantinib Afatinib Regorafenib Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Recruiting
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting
NCT02875613 Phase II Avelumab Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer Active, not recruiting
NCT02892201 Phase II Pembrolizumab Pembrolizumab in HNSCC With Residual Disease After Radiation Recruiting
NCT03074513 Phase II Atezolizumab + Bevacizumab Atezolizumab and Bevacizumab in Rare Solid Tumors Recruiting
NCT03144661 Phase I INCB062079 An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Recruiting
NCT03267498 Phase II Cisplatin + Nivolumab Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC) Recruiting
NCT03341936 Phase II Lirilumab + Nivolumab Adjuvant Nivolumab and Lirilumab in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck Recruiting
NCT03357757 Phase II Avelumab + Valproic acid Avelumab With Valproic Acid in Virus-associated Cancer (LATENT) Recruiting
NCT03422536 Phase II Ficlatuzumab Cetuximab + Ficlatuzumab Ficlatuzumab With or Without Cetuximab in Treating Patients With Cetuximab-Resistant, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Recruiting
NCT03474640 Phase I JS001 Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies Recruiting
NCT03674567 Phase Ib/II FLX475 + Pembrolizumab FLX475 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Recruiting
NCT03700294 Phase I ADCT-601 Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors Recruiting
NCT03708224 Phase II Atezolizumab + Emactuzumab Atezolizumab Phase II Study of Perioperative Immunotherapy in Patients With Advanced Non-Virally Associated Squamous Cell Carcinoma Not yet recruiting
NCT03719690 Phase II Tipifarnib Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy (AIM-HN/SEQ-HN) Recruiting
NCT03769467 Phase Ib/II Pembrolizumab + Tabelecleucel Tabelecleucel in Combination With Pembrolizumab in Subjects With EBV+ Nasopharyngeal Carcinoma (ATA129-NPC-202) Recruiting
NCT03849469 Phase I Pembrolizumab + XmAb22841 XmAb22841 A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) Recruiting